Anna M. Gutridge

Anna M. Gutridge

Auto-generated profile, based on publicly available information

Anna M. Gutridge

Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Science Signaling
Verified
Journal Article
Closed access
MKMee Jung Ko
Mee Jung Ko
TCTerrance Chiang
Terrance Chiang
AMArbaaz A. Mukadam
Arbaaz A. Mukadam
GMGrace E. Mulia
Grace E. Mulia
AGAnna M. Gutridge
Anna M. Gutridge
Richard M. Van RijnRichard M. Van Rijn
Richard M. Van Rijn
β-Arrestin signaling may mediate the fear- and anxiety-relieving effects as well as adverse events of opioids.

22 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
SCSoumen Chakraborty
Soumen Chakraborty
JDJeffrey F. DiBerto
Jeffrey F. DiBerto
AFAbdelfattah Faouzi
Abdelfattah Faouzi
SBSarah M. Bernhard
Sarah M. Bernhard
AGAnna M. Gutridge
Anna M. Gutridge
SMSusruta Majumdar
Susruta Majumdar
Dried kratom leaves are anecdotally used for the treatment of pain, opioid dependence, and alcohol use disorder. We have previously shown that kratom’s natural products (mitragynine) and semi-synthetic analogs (7-hydroxy mitragynine (7OH) and mitragynine pseudoindoxyl) are mu opioid receptor (MOR) agonists that show minimal β-arrestin2 recruitment. To further investigate the structure activity relationships of G-protein potency, efficacy, and β-arrestin2 recruitment, we diversified the mitragynine/7OH templates at the C9, -10 and -12 positions of the aromatic ring of the indole moiety. Three lead C9 analogs, synthesized by swapping the 9-methoxy group with varied substituents, namely phenyl ( SC11 ), methyl ( SC12 ), 3’-furanyl ( SC13 ), were further characterized using a panel of in vitro and ex vivo electrophysiology assays. All three compounds were partial agonists with lower efficacy than both DAMGO and morphine in heterologous G-protein assays and synaptic physiology. SC11-13 also showed lower recruitment of both β-arrestin subtypes compared to DAMGO, and in assays with limited MOR receptor reserve, the G-protein efficacy of SC11, SC12 and SC13 was comparable to buprenorphine. In mouse models, at equianalgesic doses SC13 showed MOR-dependent analgesia with potency similar to morphine without respiratory depression, hyperlocomotion, constipation, or place conditioning. Taken together, these results suggest that MOR agonists with a G-protein efficacy profile similar to buprenorphine can be developed into opioids that are effective analgesics with greatly reduced liabilities.